St. Jude Clinical Trials
Next Generation Sequencing of Normal Tissue Prospectively in Pediatric Oncology Patients
This is a non-therapeutic clinical trial that is open to St. Jude patients.
- Solid tumor or liquid tumor (cancerous or non-cancerous)
This is a non-therapeutic clinical trial open to St. Jude patients only.
Participants have been pre-identified by the primary care team as an English-speaking, four-member family unit diagnosed with TP53 mutation.
This is a non-therapeutic clinical trial that is only open to St. Jude patients
Prediction of Adverse Events in Children and Adolescents with Cancer at High Risk of Infection
This is a non-therapeutic clinical trial that is open only to St. Jude patients.
- Younger than 25 years
- Undergoing cancer therapy at St. Jude Children’s Research Hospital
- Considered to be at high risk of infection
Familial Investigations of Childhood Cancer Predisposition
Non-therapeutic clinical trial
This is a non-therapeutic clinical trial that is open to children and adults with familial cancer and to their eligible family members.
Note: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested in clinical genetic testing, please consider seeing a local genetic counselor or other genetics professional. If you have already had clinical genetic testing and meet eligibility criteria for the SJFAMILY study, as outlined below, you may enroll regardless of the results of your clinical genetic testing.
In this research study, the definition of “Familial Cancer” is met if any of the following is present:
- An individual with a history of cancer diagnosed under 26 years of age who has at least one first, second or third degree relative with a history of cancer diagnosed under 51 years of age; OR
- An individual who has been diagnosed with more than one cancer, at least one of which was diagnosed under 26 years of age; OR
- An individual with a clinical or molecular diagnosis of a known cancer predisposition syndrome; OR
- An individual with a congenital cancer that was diagnosed before 6 months of age; OR
- An individual with a rare pediatric cancer or tumor diagnosed before 26 years of age. Examples of rare pediatric tumors include (but are not limited to): carcinoma or precursor carcinoma lesions of any organ or anatomic site and cutaneous malignant cancers. Additional rare pediatric tumors to be included will be defined as any solid malignancy or borderline tumor characterized by an annual incidence of less than two occurrences per million per year (such as ectomesenchymoma).
Eligible individuals include:
- An individual who meets the definition of “Familial Cancer,” as above
- Blood relatives of the above individual with familial cancer, who are affected or unaffected by cancer
A Registry for Hemophagocytic Lymphohistiocytosis (HLH)
- Diagnosis of a primary immunodeficiency predisposed to hemophagocytic lymphohistiocytosis
- Meets at least 4 of 8 diagnostic criteria for HLH as defined by the Histiocyte Society and is receiving HLH-directed therapy
- High suspicion of isolated Central Nervous System-HLH and is receiving HLH-directed therapy